Auris Medical AG

Quick facts

Marketed products

• Intranasal Drug

Phase 3 pipeline

• AM-101 · Otolaryngology / Neurology
  AM-101 is an intratympanic injection that delivers a small-molecule NMDA receptor antagonist to the inner ear to reduce tinnitus perception.

Phase 2 pipeline

• AM-111

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Auris Medical AG portfolio CI brief
• Auris Medical AG pipeline updates RSS